Atossa Genetics (ATOS) Getting Positive Press Coverage, Report Finds

Media headlines about Atossa Genetics (NASDAQ:ATOS) have been trending positive recently, Alpha One Sentiment reports. The research group, a unit of Accern, identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atossa Genetics earned a coverage optimism score of 0.43 on Alpha One’s scale. Alpha One also assigned headlines about Atossa Genetics an impact score of 77 out of 100, meaning that recent news coverage is likely to have an effect on the stock’s share price in the immediate future.

Shares of Atossa Genetics (NASDAQ:ATOS) traded down 1.30% during midday trading on Wednesday, hitting $0.75. 133,316 shares of the company’s stock were exchanged. The company has a 50-day moving average of $1.34 and a 200-day moving average of $1.60. The firm’s market cap is $2.84 million. Atossa Genetics has a 52 week low of $0.73 and a 52 week high of $6.15.

TRADEMARK VIOLATION NOTICE: This article was posted by sleekmoney and is the property of of sleekmoney. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at

Atossa Genetics Company Profile

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

5 Day Chart for NASDAQ:ATOS

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Atossa Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *